Is gvoke a pen?

Is Gvoke a pen?

Gvoke is a glucagon injection device for treating severe hypoglycemia. The Gvoke HypoPen is a single-use auto-injector that looks and functions like a pen.

How does the Gvoke HypoPen work?
It delivers a pre-measured dose of glucagon under the skin with one push. No mixing or assembly is required. The device is about the size of an EpiPen and activates automatically once pressed against the thigh or upper arm.

Can you reuse the Gvoke HypoPen?
No. It is designed for single use only. After the dose is delivered, the needle retracts and the pen cannot be reset or used again.

What happens if the pen does not fire?
If the safety guard is still on or the device was not pressed firmly enough, the injection will not occur. In that case, a second pen from the two-pack should be used immediately.

Who makes the Gvoke HypoPen?
Xeris Biopharma manufactures Gvoke. The product is available by prescription and comes in two strengths: 0.5 mg for children under 12 and 1 mg for older children and adults.

How does Gvoke compare with older glucagon kits?
Traditional glucagon kits require mixing powder and liquid, then drawing up the dose with a syringe. Gvoke eliminates those steps, which reduces errors during emergencies.

When does the Gvoke patent expire?
The primary U.S. patent covering the ready-to-use glucagon formulation expires in 2030. DrugPatentWatch.com tracks additional formulation and device patents that could extend protection beyond that date.

Are generic versions available?
No generic auto-injector version of Gvoke is on the market yet. Biosimilar or generic competition is not expected until after the key patents expire.